Treatment with apalutamide plus androgen deprivation therapy (ADT) results in consistently favourable pain scores and less interference from pain in the daily lives of patients with metastatic castration-sensitive prostate cancer compared with placebo plus ADT, results of the phase III TITAN study have shown. Moreover, there was no difference for change seen in fatigue with apalutamide vs placebo.
The use of pembrolizumab significantly improved disease-free survival (DFS) in patients with clear-cell renal cell carcinoma (RCC) who have undergone nephrectomy, with or without metastasectomy, and were at high risk for recurrence, according to the phase III KEYNOTE-564 trial.
The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.
Chronic indwelling or intermittent bladder catheterization contributes to an increased risk of bladder cancer and related mortality, with the highest risk observed among individuals using catheters for almost 3 years as well as those with bladder calculi, as suggested in a recent study.
An MRI-targeted biopsy* plus a new risk score cuts unnecessary biopsies by half in men with positive MRI results and elevated PSA** levels in the STHLM3-MRI study. This benefit comes without missing clinically significant cancers, experts report at EAU 2021.
The β3-adrenoreceptor agonist mirabegron – a proven effective treatment for overactive bladder and neurogenic detrusor overactivity (NDO) in adults – was equally as effective in children and adolescents with NDO, a phase III study suggests.
High levels of cotinine in the urine of smokers who have undergone resection for non-muscle invasive bladder cancer (NMIBC) could be a sign of cancer recurrence, according to a study from Lebanon presented at EAU21.
Daily use of a mouthwash which has demonstrated inhibition of Neisseria gonorrhoeae (N. gonorrhoeae) growth in vitro did not reduce the risk of oropharyngeal gonorrhoea in men who have sex with men (MSM), according to results of the OMEGA* study from Australia.
In patients with high-risk muscle-invasive urothelial carcinoma (miUC) who had undergone radical surgery, disease-free survival (DFS) was longer among those who received adjuvant nivolumab vs those on placebo, according to interim findings from the phase III CheckMate 274 trial.